Abstract
We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.
Acknowledgements
Special thanks to the following and all other doctors participated in this study: Wenli Zhang (Peking University Shenzhen Hospital, Beijing, China), Bing Han (Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China), Jie Bai (Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China), Guangxun Gao (Xi jing Hospital, The Fourth Military Medical University, Shan'xi, China), Xiaomei Shen (The First People's Hospital of Yunnan province, Yunnan, China), Jie Sun (The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejing, China), Yanhong Zhao (The First Affiliated Hospital of Harbin Medical University, Heilongjiang, China), Yuping Zhong (Beijing Chao-yang Hospital, Capital Medical University, Beijing, China), Kejie Zhang (Zhongshan Hospital Affiliated to Xiamen University, Fujian, China), Weiyan Zheng (The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, China), Li Wang (The First Affiliated Hospital of Chongqing Medical University, Chongqing, China), Ningning Li (Beijing Chuiyangliu Hospital, Beijing, China), Shuxia Chen (The First People's Hospital of Shangqiu City, Henan, China), Saiyinqimuge (Ordos Central Hospital, Inner Mongolia, China), Haiping Yang (First Affiliated Hospital and College of Clinical Medicine Henan University of Science and Technology, Henan, China), Li Zhou (Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China), Wensheng Wang (Peking University First Hospital, Beijing, China), Zhongxia Huang (Beijing Chao-yang Hospital, Capital Medical University, Beijing, China), Youjing Feng (Gansu Provincial People's Hospital, Lanzhou, Gansu, China), Zhengrong Liu (Anyang People's Hospital, Henan, China), Aijun Liu (Beijing Chao-yang Hospital, Capital Medical University, Beijing, China), Jinhai Ren (The Second Hospital of Hebei Medical University, Hebei, China), Hui Geng (Qinghai University Affiliated Hospital, Qinghai, China), Suning Chen (The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China), Hui Xiao (Zhongnan Hospital of Wuhan University, Hubei, China), Xuelan Zuo (Zhongnan Hospital of Wuhan University, Hubei, China).
Disclosure statement
The authors report no conflict of interest.
Data availability statement
The datasets analyzed during the current study are available from the corresponding author on reasonable request.